Draft:Abhishesh Kumar Mehata
Submission declined on 8 May 2024 by Iwaqarhashmi (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|
Submission declined on 27 January 2022 by Nomadicghumakkad (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by Nomadicghumakkad 2 years ago. |
Dr. Abhishesh Kumar Mehata (born April 16, 1992) is a pharmaceutical engineer, scientist, inventor and researcher at the Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology, BHU.[1] He is a former research scientist at the Sun pharmaceuticals research and development center. His area of research is to develop nanomedicine for the targeted therapy of breast cancer. He has more than 70 research publications in reputed international journals.[2][3][4]
Mehata has received a master's degree in Pharmaceutics from the Indian Institute of Technology, BHU, under the supervision of Dr. M.S. Muthu.[5] He is among the world's top 2% scientists, according to a list compiled by Stanford University.[6][7] Mehata has been ranked among the top 100 university scientists.[8] He is editor of Journal of Biomaterials [9], Cardiovascular therapeutics[10], review editor of nanomaterials (Frontiers in nanotechnology) and former student editor of Pharmstudent.[11]
His recently developed targeted nanomedicine has demonstrated promising outcomes in preclinical studies for breast cancer therapy.[12] He has also assisted the researcher in understanding immunological targeting for COVID-19 immunotherapy.[13]
References
[edit]- ^ "Loop | Abhishesh Kumar Mehata". loop.frontiersin.org. Retrieved 2022-01-23.
- ^ "Abhishesh kumar Mehata". scholar.google.co.in. Retrieved 2022-01-23.
- ^ "A. K. Mehata | Semantic Scholar". www.semanticscholar.org. Retrieved 2022-01-23.
- ^ "Abhishesh Kumar Mehata | Scinapse". www.scinapse.io. Retrieved 2022-01-24.
- ^ "msmuthu.phe | Indian Institute of Technology(BHU)". iitbhu.ac.in. Retrieved 2022-01-23.
- ^ "14 scientists from IIT-BHU in world's top 2% scientists' list by Stanford University". Deccan Herald. 2020-11-11. Retrieved 2022-01-23.
- ^ "14 scientists from IIT-BHU in world's top 2 pc scientists' list by Stanford University - Times of India". The Times of India. 11 November 2020. Retrieved 2022-01-23.
- ^ "Abhishesh Kumar Mehata - AD Scientific Index 2022". www.adscientificindex.com. Retrieved 2022-01-23.
- ^ "Editorial Board : Journal of Biomaterials". www.journalofbiomaterials.org. Retrieved 2022-01-23.
- ^ "cdtp - Editorial board". Hindawi. Retrieved 2024-04-12.
- ^ "Editorial Board". old.iitbhu.ac.in. Retrieved 2022-01-23.
- ^ "आईआईटी बीएचयू का झींगे से स्तन कैंसर की दवा बनाने का दावा". Hindustan (in Hindi). Retrieved 2022-01-23.
- ^ Mehata, Abhishesh Kumar; Viswanadh, Matte Kasi; Priya, Vishnu; Vikas; Muthu, Madaswamy S (2021-09-01). "Harnessing immunological targets for COVID-19 immunotherapy". Future Virology. 16 (9): 619–640. doi:10.2217/fvl-2021-0048. ISSN 1746-0794. PMC 8375415. PMID 34447458.